The RITUXAN for RA EXPERIENCE Program

through Genentech
Rheumatology
Access Solutions

$4,000 per
12-month period
toward the cost of
Rituxan for eligible patients

Indication

Rituxan^® (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is not recommended for treatment of patients with severe active infections.

Important Safety Information

RITUXAN administration can result in serious, including fatal, adverse reactions. These include: infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy (PML).

Warnings and Precautions

Rituxan administration can also result in additional serious, including fatal, adverse reactions including:

hepatitis B reactivation
other infections including bacterial, fungal, new or reactivated viral infections
cardiovascular events

Patients should be closely observed for signs of infection if biologic agents and /or DMARDs other than methotrexate are used concomitantly

Common adverse reactions include infusion reactions and infections

For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.

Print Page

Infusion safety data over 6 courses

Proportion of patients with infusion-related reactions decreased with subsequent courses of Rituxan

Data were available for 3189 patients. A total of 2928 patients had >1 year of observations, 2472 patients had >2 years, 1540 patients had >3 years, 685 patients had >4 years, 587 patients had >5 years and 310 patients had >6 years

Date of treatment initiation differed among studies included in this pooled analysis. To date a limited number of patients have received >7 years of treatment and up to 15 courses of treatment.

SAFETY INFORMATION: Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and up to one year following Rituxan based therapy.

Rituxan can cause severe, including fatal, infusion reactions. Severe reactions typically occurred during the first infusion with time to onset of 30 to 120 minutes.

References

1.: Rituxan [package insert]. South San Francisco, CA: Biogen Idec Inc. and Genentech USA, Inc.; February 2010.
7.: van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab: follow-up of the RA clinical trials and retreatment population. Presented at European League Against Rheumatism Conference; June 16-19, 2010; Rome, Italy.